What is ABUS stock price today?

Visit our real-time dashboard for the current ABUS stock price and live market data.

Is ABUS stock going up or down today?

ABUS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ABUS stock now?

The decision to buy ABUS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ABUS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ABUS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ABUS stock overvalued or undervalued?

ABUS currently trades at a P/E ratio of 5.39, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if ABUS is fairly priced.

What is ABUS's P/E ratio?

ABUS has a price-to-earnings (P/E) ratio of 5.39, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is ABUS's market cap?

ABUS (Arbutus Biopharma Corp) has a market capitalization of $0.88 billion, making it a small-cap stock.

What is ABUS's price to book ratio?

ABUS trades at a price-to-book (P/B) ratio of 3.33, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ABUS pay dividends?

ABUS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ABUS's dividend yield?

ABUS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ABUS stock a good long-term investment?

ABUS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ABUS's revenue growth rate?

Revenue growth data for ABUS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ABUS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ABUS?

Key risks for ABUS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ABUS compare to its competitors?

Compare ABUS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ABUS's performance and positioning.

What is ABUS's stock price target for 2026?

Visit our prediction page for AI-powered price targets for ABUS with bull, base, and bear case scenarios.

What do analysts say about ABUS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ABUS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ABUS's next earnings report?

ABUS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ABUS - Arbutus Biopharma Corp

NYSE * Healthcare * Biotechnology

$0.00

+$0.00 (+0.00%)

About Arbutus Biopharma Corp

Arbutus Biopharma Corp (ABUS) common stock

Price Chart

Loading chart...

ABUS Key Statistics

Market Cap

$882.99M

P/E Ratio

5.39

P/B Ratio

3.33

How ABUS Compares to Peers

ABUS has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued

ABUS is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

N/A

of 0

Growth Rank

N/A

of 0

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ABUS(This stock)	$882.99M	5.4	0%	0.0%	-
AMGNAmgen Inc	$188.67B	24.3	0%	0.0%	vs AMGN
GILDGilead Sciences	$160.15B	17.5	0%	0.0%	vs GILD
VRTXVertex Pharmaceuticals	$106.87B	29.7	0%	0.0%	vs VRTX
REGNRegeneron Pharmaceuticals	$59.10B	13.9	0%	0.0%	vs REGN
BIIBBiogen Inc	$29.33B	21.4	0%	0.0%	vs BIIB

Data Updated: July 20, 2026 at 1:56 PM EDT

Ready to invest in ABUS?

Commission-free trading available. Affiliate links.

ABUS Lician Score

10% confidence

5.0/10

Neutral

ABUS has a Lician Score of 5/10 (Average). Areas of concern: Growth.

value

5.0

growth

3.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ABUSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ABUS Financial Snowflake

5-axis analysis across key investment dimensions

4.6/10

Neutral

5.0

Value

Valuation vs. sector peers

3.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ABUS

Dashboard

Enter a ticker to analyze